Javier Fernández-Ruiz

Best Publications

• Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

  Orrin Devinsky;Maria Roberta Cilio;Helen Cross;Javier Fernandez-Ruiz

  1113
  Citations

• Pharmacological and biochemical interactions between opioids and cannabinoids.

  Jorge Manzanares;Javier Corchero;Julian Romero;Javier J. Fernández-Ruiz

  479
  Citations

• Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

  Isabel Lastres-Becker;Francisco Molina-Holgado;José A. Ramos;Raphael Mechoulam

  472
  Citations

• Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

  Javier Fernández-Ruiz;Julián Romero;Guillermo Velasco;Rosa M. Tolón

  445
  Citations

• Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration.

  Suzana Gispert;Filomena Ricciardi;Alexander Kurz;Mekhman Azizov

  438
  Citations

• Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

  Javier Palazuelos;Tania Aguado;M. Ruth Pazos;Boris Julien

  436
  Citations

• Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

  Javier Fernández‐Ruiz;Onintza Sagredo;M. Ruth Pazos;Concepción García

  392
  Citations

• Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism

  Agnieszka Jazwa;Ana I. Rojo;Nadia G. Innamorato;Marlen Hesse

  329
  Citations

• The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors

  A. Castillo;M.R. Tolón;J. Fernández-Ruiz;J. Romero

  324
  Citations

• Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine.

  Sara González;Maria Grazia Cascio;Javier Fernández-Ruiz;Filomena Fezza

  320
  Citations

• Cannabinoid tolerance and dependence: A review of studies in laboratory animals

  Sara González;Maribel Cebeira;Javier Fernández-Ruiz

  268
  Citations

• Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.

  Henrik H. Hansen;Patricia C. Schmid;Petra Bittigau;Isabel Lastres-Becker

  258
  Citations

• Downregulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment

  F.Rodríguez De Fonseca;M.A. Gorriti;J.J. Fernández-Ruiz;T. Palomo

  238
  Citations

• Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease

  Cristina Blázquez;Anna Chiarlone;Onintza Sagredo;Tania Aguado

  229
  Citations

• Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease

  C García;C Palomo-Garo;M García-Arencibia;JA Ramos

  223
  Citations

• Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

  Onintza Sagredo;Sara González;Ilia Aroyo;María Ruth Pazos

  221
  Citations

• Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.

  Javier Fernández-Ruiz;Mariluz Hernández;José A. Ramos

  202
  Citations

• Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors

  Onintza Sagredo;José A. Ramos;Alessandra Decio;Raphael Mechoulam

  189
  Citations

• The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects

  Julián Romero;Isabel Lastres-Becker;Rosario de Miguel;Fernando Berrendero

  185
  Citations

• Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.

  Vincenzo Di Marzo;Isabel Lastres-Becker;Tiziana Bisogno;Luciano De Petrocellis

  182
  Citations